Investment Rating - The report maintains an "Outperform" rating for the company [4][11]. Core Insights - The company continues to experience robust revenue growth, with a projected revenue of RMB 2.698 billion for 2025, reflecting a year-on-year increase of 30.6% [3][4]. - Net profit attributable to shareholders is expected to reach RMB 870 million in 2025, representing a growth of 29.2% compared to the previous year [3][4]. - The target price for the stock is set at RMB 333.05, with a target PE of 54X for 2025 [4][11]. Financial Summary - Total revenue for the first three quarters of 2025 was RMB 1.867 billion, with a net profit of RMB 623 million [4][11]. - Q3 2025 revenue was RMB 654 million, with a net profit of RMB 198 million [4][11]. - Forecasted EPS for 2025-2027 is RMB 6.17, RMB 8.09, and RMB 10.50 respectively [4][11]. Business Development - The volume of PFA surgeries is rapidly increasing, with expectations to exceed 5,000 procedures in 2025 [12][4]. - The company has expanded its promotion team to over 200 sales and on-site engineers, aiming for a 10%-20% annual increase in on-site volume per engineer [12][4]. - Increased investment in PFA promotion and R&D is evident, with Q3 2025 sales expenses at RMB 125 million and R&D expenses at RMB 98 million [13][4]. Market Position - The company holds approximately 20% market share in coronary business and over 30% in tumor intervention access products [14][4]. - Growth in the coronary and peripheral business is driven by existing product lines and the introduction of iterative products post volume-based procurement [14][4].

Core Viewpoint - The company reported strong financial performance for Q1-Q3 2025, with significant year-over-year growth in revenue and net profit, driven by the successful launch of high-end products and an increase in market share in key business segments [1][2]. Financial Performance - For Q1-Q3 2025, the company achieved revenue of 1.867 billion yuan, representing a year-over-year increase of 22.47%, and a net profit attributable to shareholders of 623 million yuan, up 18.02% year-over-year [1]. - In Q3 2025, the company recorded revenue of 654 million yuan, a year-over-year increase of 24.77%, and a net profit of 198 million yuan, reflecting a year-over-year growth of 6.77% [1]. Business Growth Drivers - The launch of PFA and other high-end products has led to a steady increase in market share in the coronary and peripheral business segments, with an annual market share growth of 1-2 percentage points [2]. - The overall market share for the coronary business reached approximately 20%, while the market share for tumor intervention products in the peripheral vascular business exceeded 30% [2]. Research and Development - The company increased its R&D expenditure to 255 million yuan, accounting for 13.7% of revenue, focusing on expanding clinical indications for PFA ablation catheters and developing next-generation ablation devices [3]. - The company has successfully registered its three-dimensional electrophysiology system and PFA ablation solutions in Indonesia and is progressing towards CE certification for its systems, expected in Q2 2026 and Q2 2027 [3]. Future Revenue Projections - Revenue forecasts for 2025-2027 are 2.604 billion yuan, 3.308 billion yuan, and 4.197 billion yuan, with year-over-year growth rates of 26.06%, 27.02%, and 26.87% respectively [4]. - Net profit projections for the same period are 856 million yuan, 1.096 billion yuan, and 1.398 billion yuan, with growth rates of 27.16%, 28.05%, and 27.55% respectively [4].